Erectile Dysfunction Clinical Trial
Official title:
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
NCT number | NCT06425211 |
Other study ID # | BMGC-6 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 30, 2021 |
Est. completion date | December 2024 |
The objective of this clinical trial is to evaluate the effectiveness of pelvic floor therapy for the management of erectile dysfunction and premature ejaculation in patients with erectile dysfunction and premature ejaculation. The main question to answer is: What is the effectiveness of pelvic floor therapy (electrostimulation, biofeedback, and therapeutic exercise) for the treatment of patients with erectile dysfunction and or premature ejaculation? Patients will: - Have an initial consultation of pelvic floor rehabilitation before therapy. - Be given pelvic floor therapy. - Have a secondary consultation of pelvic floor rehabilitation after therapy. Three intervention groups will be included: Group 1: Patients with premature ejaculation Group 2: Patients with erectile dysfunction Group 3: Patients with erectile dysfunction and premature ejaculation.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: Overall: - Men over 18 years of age - Erectile dysfunction or premature ejaculation for at least 6 months - Sexual activity with a heterosexual partner at least once a week - Signing of informed consent before the start of the study For the premature ejaculation group: - Premature ejaculation according to the International Society of Sexual Medicine (ISSM) criteria - Premature Ejaculation Diagnosis Tool (PEDT) questionnaire score greater than 11 For the erectile dysfunction group: - Clinical diagnosis of primary erectile dysfunction - International Index Erectile Function - Erectile Function domain (IIEF-EF) score less than 26 Exclusion Criteria: - Pharmacological treatment for erectile dysfunction or premature ejaculation in the last 3 months - Erection Hardness Score (EHS) greater than 3 for patients with erectile dysfunction - History of hypogonadism or suspected hypogonadism due to Aging Males Symptoms (AMS) score greater than 36 for patients with erectile dysfunction - History of pelvic radiotherapy - Pacemaker or cardiac arrhythmia, epilepsy - History of spinal cord trauma or spinal surgeries. - Inability to attend therapies or controls - Illiteracy or cognitive disability that prevents you from completing the questionnaires - Psychiatric, psychological disorders, or cognitive deficiencies - Injuries in the area of application of the therapy - Active pelvic organ cancer |
Country | Name | City | State |
---|---|---|---|
Colombia | Boston Medical Group Colombia | Bogotá | Cundinamarca |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Group |
Colombia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in baseline intravaginal latency time (IVLT) | Change in baseline intravaginal latency time (IVLT) at the end of therapy. (Groups 1,3) | 12 weeks | |
Primary | Change in International Index of Erectile Dysfuntion - Erectile Dysfunction domain (IIEF-EF) score | International Index of Erectile Dysfuntion - Erectile Dysfunction domain (IIEF-EF) score change at the end of therapy. (Groups 2,3) | 12 weeks | |
Secondary | Change in baseline intravaginal latency time (IVLT) at follow-up | Change in IVLT at 3 and 6 months of follow-up. (Groups 1,3) | 3 and 6 months of follow-up. | |
Secondary | Change Premature Ejaculation Perfil (PEP) score | Change in baseline PEP score at the end of therapy, 3 and 6 months of follow-up. (Groups 1,3) | 12 weeks, 3 and 6 months follow-up. | |
Secondary | Change in Premature Ejaculation Diagnosis Tool (PEDT) questionnnaire score | Change in baseline PEDT questionnaire score at the end of therapy, 3 and 6 months follow-up. (Groups 1,3) | 12 weeks, 3 and 6 months follow-up. | |
Secondary | Change Intracavity Assessment | Change in the parameters of the baseline Intracavity Assessment at the end of therapy, 3 and 6 months follow-up. | 12 weeks, 3 and 6 months follow-up. | |
Secondary | Side Effects | Incidente of side effects related to therapy. | 12 weeks, 3 and 6 months follow-up. | |
Secondary | Change in International Index of Erectile Dysfuntion - Erectile Dysfunction domain (IIEF-EF) score at follow-up | International Index of Erectile Dysfuntion - Erectile Dysfunction domain (IIEF-EF) score change at the 3 and 6 months of follow-up. (Groups 2,3) | 3 and 6 months of follow-up. | |
Secondary | Change in Erection Hardness Score (EHS) | Increase of 1 point in the baseline EHS at the end of therapy, 3 and 6 months of follow-up. (Groups 2,3) | 12 weeks, 3 and 6 months of follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |